CClinicalTrials.gg
Sign In
RecruitingNCT06173453JIROVECIUpdated Dec 15, 2023

Factors Associated With Survival in Patients Having Pneumocystis Jirovecii

An observational study in Pneumocystis Jirovecii Infection, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-15.

Sponsored by University Hospital, Strasbourg, France · Observational

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Started Jan 2023; still recruiting 3 years 9 months later.
Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
300
Ages
18 Years and older
Sex
All
01

Study summary

Pneumocystis jirovecii is a fungus that can colonize the airways of some patients and be responsible for a disease called pneumocystosis in other patients and mainly in immunocompromised patients.

Pneumocystosis was mainly linked to HIV in the 1990s, but with the advent of new immunosuppressive molecules used in cancers or autoimmune diseases and with the increase in the number of transplants, the epidemiology has changed in recent years.

Studies on P. jirovecii-related mortality are only based on patients with pneumocystosis. As a result, patients who are simply colonized or patients who are sick but not treated are not taken into account in these studies. The investigators therefore wish to study the overall mortality at six weeks and at three months in all patients with a positive sample for P. jirovecii

02

Conditions studied

  • Pneumocystis Jirovecii Infection

Keywords

  • P jirovecii Infection
  • Pneumocystis Infections
  • Pneumocystis jirovecii Infection
  • Pneumocystis jirovecii
  • Pneumonia
  • Pneumocystis
03

In context

Infections

6,687 studies on the registry are indexed under Infections; 807 are open to participants now.

This study's planned enrollment of 300 is above the median of 240 across 2,136 observational studies indexed under Infections.

Browse Infections studies →

Lead sponsor

University Hospital, Strasbourg, France is the lead sponsor of 966 studies on the registry; 342 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with a positive respiratory sample for P. jirovecii

Inclusion criteria

  • Adult patients with a positive respiratory sample for P. jirovecii cared for in Strasbourg University Hospitals between 01/01/2016 and 31/12/2018. Positive samples are defined as a direct examination finding cysts or trophozoites after staining with May-Grunewald-Giemsa and/or Gomori-Grocott, a positive P. jirovecii PCR on sputum, tracheal aspirates or bronchial fluid -alveolar
  • Subject not objecting to the reuse of their data for scientific research purposes.

Exclusion criteria

Exclusion criteria:

  • Subject having expressed its opposition to the reuse of its data for scientific research purposes.
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
300 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Survival at six weeks and three months after infection

    Time frame: six weeks after infection

07

Study locations

1 of 1 sites recruiting
  • Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France
    Strasbourg, 67091, France
    • François DANION, MD · Contact · francois.danion@chru-strasbourg.fr · 33 3 69 55 15 88
    • François DANION, MD · Principal investigator
    • Victor GERBER, MD · Sub investigator
    • Valentin GREIGERT, Statistician · Sub investigator
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06173453
Lead sponsor
University Hospital, Strasbourg, France
Responsible party
Sponsor
First posted
Dec 15, 2023
Start date
Jan 1, 2023
Primary completion
Aug 10, 2025 (estimated)
Completion
Oct 10, 2025 (estimated)
Last update
Dec 15, 2023

Study contacts

François DANION, MD
Contact
Francois.danion@chru-strasbourg.fr
33 3 69 55 15 88

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Infections→

Other studies from this sponsor

University Hospital, Strasbourg, France

Start the discussion